Johnson & Johnson (JNJ)
Why One Analyst Thinks Johnson & Johnson Reaches $280
Johnson & Johnson ( NYSE:JNJ ) has been one of healthcare's standout performers over the past year, with shares up 48% over the past 12 months and 16% year-to-date.
Johnson & Johnson $JNJ Shares Bought by Brown Brothers Harriman & Co.
Brown Brothers Harriman and Co. raised its holdings in Johnson and Johnson (NYSE: JNJ) by 2.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 374,940 shares of the company's stock after purchasing an additional 8,665 shares during the quarter. Brown Brothers Harriman
Bank of Hawaii Reduces Stock Holdings in Johnson & Johnson $JNJ
Bank of Hawaii decreased its position in Johnson and Johnson (NYSE: JNJ) by 5.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,571 shares of the company's stock after selling 2,152 shares during the period. Bank of
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
The 5 Safest Dividend Kings Are the Only Stocks to Buy Now
The stock market could face serious trouble as 2026 heads into the second quarter under duress.
American Investment Services Inc. Purchases 2,152 Shares of Johnson & Johnson $JNJ
American Investment Services Inc. raised its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 10.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,697 shares of the company's stock after purchasing an additional 2,152 shares during the quarter.
Johnson & Johnson (NYSE:JNJ) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Johnson and Johnson (NYSE: JNJ - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-seven research firms that are presently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has assigned a strong
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
Johnson & Johnson seeks EMA nod to expand Tecvayli monotherapy use in earlier-line RRMM, backed by phase III MajesTEC-9 data showing strong survival gains.
Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
J&J gains EU approval to expand Akeega use to treat patients with BRCA-mutated metastatic hormone-sensitive prostate cancer.
Dividend Aristocrats in a Shaky Market: KO, PG, JNJ, and 2 Others Built to Last
The market's fear gauge tells the story clearly. The VIX hit 21.15 as of March 4, 2026, up 29.4% in a single month.
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $239.63, denoting a -2.31% move from the preceding trading day.
